Quadrant Capital Group’s Novavax NVAX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-5,293
| Closed | -$43.1K | – | 2126 |
|
|
2026
Q1 | $43.1K | Sell |
5,293
-582
| -10% | -$5.28K | ﹤0.01% | 1753 |
|
|
2025
Q4 | $39.5K | Sell |
5,875
-282
| -5% | -$2.13K | ﹤0.01% | 1766 |
|
|
2025
Q3 | $53.4K | Buy |
+6,157
| New | +$47.9K | ﹤0.01% | 1650 |
|
|
2025
Q2 | – | Sell |
-2,016
| Closed | -$12.9K | – | 2173 |
|
|
2025
Q1 | $12.9K | Buy |
2,016
+287
| +17% | +$2.37K | ﹤0.01% | 2156 |
|
|
2024
Q4 | $13.9K | Sell |
1,729
-81
| -4% | -$781 | ﹤0.01% | 2026 |
|
|
2024
Q3 | $22.9K | Sell |
1,810
-306
| -14% | -$3.95K | ﹤0.01% | 1838 |
|
|
2024
Q2 | $26.8K | Buy |
2,116
+1,152
| +120% | +$11.6K | ﹤0.01% | 1722 |
|
|
2024
Q1 | $4.61K | Buy |
964
+465
| +93% | +$2.16K | ﹤0.01% | 2345 |
|
|
2023
Q4 | $2.4K | Sell |
499
-3,332
| -87% | -$20.4K | ﹤0.01% | 2443 |
|
|
2023
Q3 | $27.7K | Sell |
3,831
-514
| -12% | -$4.11K | ﹤0.01% | 1556 |
|
|
2023
Q2 | $32.3K | Buy |
4,345
+722
| +20% | +$5.68K | ﹤0.01% | 1471 |
|
|
2023
Q1 | $25.1K | Buy |
3,623
+3,023
| +504% | +$27.8K | ﹤0.01% | 1577 |
|
|
2022
Q4 | $6.17K | Buy |
600
+338
| +129% | +$5.96K | ﹤0.01% | 2150 |
|
|
2022
Q3 | $5K | Sell |
262
-87
| -25% | -$3.77K | ﹤0.01% | 2143 |
|
|
2022
Q2 | $18K | Buy |
349
+87
| +33% | +$4.51K | ﹤0.01% | 1369 |
|
|
2022
Q1 | $19K | Buy |
262
+92
| +54% | +$8.2K | ﹤0.01% | 1363 |
|
|
2021
Q4 | $24K | Sell |
170
-56
| -25% | -$9.62K | ﹤0.01% | 1231 |
|
|
2021
Q3 | $47K | Buy |
226
+60
| +36% | +$13.2K | 0.01% | 888 |
|
|
2021
Q2 | $35K | Buy |
166
+61
| +58% | +$11.2K | 0.01% | 984 |
|
|
2021
Q1 | $19K | Buy |
105
+27
| +35% | +$5.38K | ﹤0.01% | 1200 |
|
|
2020
Q4 | $9K | Sell |
78
-12
| -13% | -$1.27K | ﹤0.01% | 1440 |
|
|
2020
Q3 | $10K | Buy |
90
+12
| +15% | +$1.46K | ﹤0.01% | 1236 |
|
|
2020
Q2 | $7K | Buy |
+78
| New | +$2.98K | ﹤0.01% | 1505 |
|
|
2016
Q4 | – | Sell |
-48
| Closed | -$1K | – | 2048 |
|
|
2016
Q3 | $1K | Hold |
48
| – | – | ﹤0.01% | 1733 |
|
|
2016
Q2 | $6K | Buy |
+48
| New | +$5.5K | ﹤0.01% | 1174 |
|
|
2016
Q1 | – | Sell |
-35
| Closed | -$5K | – | 1916 |
|
|
2015
Q4 | $5K | Buy |
+35
| New | +$5.39K | ﹤0.01% | 1108 |
|
Other funds holding NVAX
SCM
S
Quadrant Capital Group's NVAX Position: Q2 2026 in Review
Quadrant Capital Group sold out of Novavax (NVAX) in Q2 2026, closing a stake of 5,293 shares — an estimated $43.1K sold.
Quadrant Capital Group first reported a position in NVAX in Q4 2015 and held it in 26 quarters. The position peaked at $53.4K in Q3 2025. 266 funds tracked by Wall St. Rank hold NVAX as of Q2 2026.
- Quadrant Capital Group reported no remaining Novavax position as of Q2 2026 after selling out during the quarter.
- Quadrant Capital Group sold 5,293 Novavax shares in Q2 2026, an estimated $43.1K.
- Quadrant Capital Group first reported a position in Novavax in Q4 2015 and held it in 26 quarters.
- Quadrant Capital Group's Novavax position peaked at $53.4K in Q3 2025.
- 266 funds tracked by Wall St. Rank held Novavax as of Q2 2026.
Based on Quadrant Capital Group's 13F filing for Q2 2026, filed 14 Aug 2026.